Carole D Mitnick

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru
    Carole Mitnick
    Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 348:119-28. 2003
  2. doi request reprint Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study
    Mercedes C Becerra
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA
    Lancet 377:147-52. 2011
  3. pmc Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method
    Carole D Mitnick
    Dept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Partners In Health, Boston, MA, USA
    Eur Respir J 48:1160-1170. 2016
  4. pmc Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality
    Carole D Mitnick
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 8:e58664. 2013
  5. pmc Randomized trials to optimize treatment of multidrug-resistant tuberculosis
    Carole D Mitnick
    Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 4:e292. 2007
  6. pmc Comprehensive treatment of extensively drug-resistant tuberculosis
    Carole D Mitnick
    Harvard Medical School, Boston, USA
    N Engl J Med 359:563-74. 2008
  7. pmc Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence
    Molly F Franke
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 56:770-6. 2013
  8. pmc Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment
    Molly F Franke
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Infect Dis 46:1844-51. 2008
  9. doi request reprint Tuberculosis in children exposed at home to multidrug-resistant tuberculosis
    Mercedes C Becerra
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA
    Pediatr Infect Dis J 32:115-9. 2013
  10. doi request reprint Recurrence after treatment for pulmonary multidrug-resistant tuberculosis
    Mercedes C Becerra
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA
    Clin Infect Dis 51:709-11. 2010

Research Grants

Detail Information

Publications26

  1. ncbi request reprint Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru
    Carole Mitnick
    Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 348:119-28. 2003
    ..We evaluated the results of community-based therapy for multidrug-resistant tuberculosis in a poor section of Lima, Peru...
  2. doi request reprint Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study
    Mercedes C Becerra
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA
    Lancet 377:147-52. 2011
    ..WHO recommends contact investigation in close contacts of patients with MDR and XDR tuberculosis. We aimed to assess the burden of tuberculosis disease in household contacts of such patients...
  3. pmc Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method
    Carole D Mitnick
    Dept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Partners In Health, Boston, MA, USA
    Eur Respir J 48:1160-1170. 2016
    ..Monthly monitoring of sputum cultures from patients receiving MDR-TB treatment is recommended. Expanded laboratory capacity is needed for high-quality culture, and for smear microscopy and rapid molecular tests...
  4. pmc Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality
    Carole D Mitnick
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 8:e58664. 2013
    ..Analysis of observational data may inform the definition of an optimized regimen...
  5. pmc Randomized trials to optimize treatment of multidrug-resistant tuberculosis
    Carole D Mitnick
    Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 4:e292. 2007
  6. pmc Comprehensive treatment of extensively drug-resistant tuberculosis
    Carole D Mitnick
    Harvard Medical School, Boston, USA
    N Engl J Med 359:563-74. 2008
    ..We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among patients who were referred for individualized outpatient therapy in Peru...
  7. pmc Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence
    Molly F Franke
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 56:770-6. 2013
    ..A better understanding of treatment-related factors associated with an elevated risk of recurrent tuberculosis after cure is urgently needed to optimize MDR tuberculosis therapy...
  8. pmc Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment
    Molly F Franke
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Infect Dis 46:1844-51. 2008
    ....
  9. doi request reprint Tuberculosis in children exposed at home to multidrug-resistant tuberculosis
    Mercedes C Becerra
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA
    Pediatr Infect Dis J 32:115-9. 2013
    ..With limited access to MDR-TB treatment, likely millions of children share the experience of chronic exposure to an infectious patient...
  10. doi request reprint Recurrence after treatment for pulmonary multidrug-resistant tuberculosis
    Mercedes C Becerra
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA
    Clin Infect Dis 51:709-11. 2010
    ..2% (95% confidence interval, 3.0%-8.2%) experienced true relapse. This is an upper-bound estimate of relapse on which new regimens must improve...
  11. pmc Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment
    Dylan B Tierney
    Division of Global Health Equity, Brigham and Women s Hospital, Boston, Massachusetts, United States of America Partners In Health, Boston, Massachusetts, United States of America Socios En Salud Sucursal Peru, Lima, Peru
    PLoS ONE 9:e108035. 2014
    ..These results support the use of an aggressive regimen as the optimized background regimen in trials of new anti-TB drugs. ..
  12. pmc Long-term follow-up for multidrug-resistant tuberculosis
    Sonya S Shin
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Emerg Infect Dis 12:687-8. 2006
    ..Among 86 patients considered cured after completion of treatment, 97% remain healthy; 1 patient relapsed. Employment increased from 34% before treatment to 71%. We observed favorable long-term outcomes among MDR-TB patients...
  13. pmc Counting pyrazinamide in regimens for multidrug-resistant tuberculosis
    Molly F Franke
    1 Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts
    Ann Am Thorac Soc 12:674-9. 2015
    ..Whether this regimen should be supplemented in the absence of likely PZA effectiveness is an open question...
  14. ncbi request reprint Implementation and initial evaluation of a Web-based nurse order entry system for multidrug-resistant tuberculosis patients in Peru
    Sharon S Choi
    Program in Infectious Disease and Social Change, Dept of Social Medicine, Harvard Medical School, 643 Huntington Avenue, Boston, MA 02115, USA
    Stud Health Technol Inform 107:202-6. 2004
    ..Additionally, the nurse expressed satisfaction with the order entry system and its ease of use. The decrease in error rates and user satisfaction regarding the system are promising measures of our order entry system's success...
  15. pmc Tuberculosis pharmacotherapy: strategies to optimize patient care
    Carole D Mitnick
    Department of Global Health and Social Medicine, Harvard Medical School, 643 Huntington Ave, 4th Floor, Boston, MA 02215, USA
    Expert Opin Pharmacother 10:381-401. 2009
    ..Multi-drug resistant TB and TB in individuals coinfected with HIV present additional treatment challenges...
  16. pmc Epidemiology and treatment of multidrug resistant tuberculosis
    Carole D Mitnick
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts 02199, USA
    Semin Respir Crit Care Med 29:499-524. 2008
    ..Further delays in scale-up, however, risk continued generation and transmission of resistant tuberculosis, as well as associated morbidity and mortality...
  17. pmc Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis
    Karen R Jacobson
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 51:6-14. 2010
    ..We conducted a meta-analysis to assess XDR TB treatment outcomes and to identify therapeutic approaches associated with favorable responses...
  18. ncbi request reprint Preliminary clinical outcomes from the Peruvian National Cataract Elimination Plan
    Tomasz P Stryjewski
    Oliver Wendell Holmes Society, Harvard Medical School, Boston, Massachusetts, United States of America
    Rev Panam Salud Publica 28:282-8. 2010
    ..to evaluate the clinical outcomes of a publicly funded cataract elimination program...
  19. pmc A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment
    Chunling Lu
    Division of Global Equity, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 8:e56074. 2013
    ..The objective of this review is to provide cost evidence that is needed for national TB programs to budget for optimal monitoring strategies...
  20. pmc Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis
    Maha R Farhat
    Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Microbiol 54:727-33. 2016
    ..Further, the differential effects of gyr mutations on the activity of early- and later-generation fluoroquinolones requires further investigation and could inform the selection of a fluoroquinolone for treatment. ..
  21. pmc Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru
    Dylan B Tierney
    Brigham and Women s Hospital, Boston, MA, USA
    Glob Pediatr Health 3:2333794X16674382. 2016
    ..Among 90 adolescents from Lima, Peru, 68 (75.6%) achieved cure or completion of treatment. Unsuccessful treatment was less common in the Peru cohort than previously described in the literature...
  22. pmc Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients
    Gustavo E Velásquez
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother . 2016
    ..95 (95% confidence interval, 0.74-5.11), but this result was not statistically significant. These findings underscore the need for improved diagnostics for routine use in programmatic settings...
  23. pmc Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda
    Carole D Mitnick
    Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, United States of America
    PLoS ONE 11:e0155968. 2016
    ..We present the third updated Research Agenda for the programmatic management of drug-resistant TB (PMDT), assembled through a literature review and survey...
  24. pmc Multidrug-resistant tuberculosis management in resource-limited settings
    Eva Nathanson
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Emerg Infect Dis 12:1389-97. 2006
    ..In resource-limited settings, treatment of MDRTB provided through, or in collaboration with, national TB programs can yield results similar to those from wealthier settings...
  25. ncbi request reprint Are second-line drugs necessary to control multidrug-resistant tuberculosis?
    Edward A Nardell
    J Infect Dis 194:1194-6. 2006
  26. pmc Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda
    Frank G J Cobelens
    KNCV Tuberculosis Foundation, The Hague, The Netherlands
    PLoS Med 5:e150. 2008

Research Grants2

  1. Randomized Trial of High-Dose Rifampin in Patients with New, Smear-Positive TB
    Carole Mitnick; Fiscal Year: 2007
    ..Moreover, this trial will contribute to the existing evidence base about possible surrogate endpoints, thereby simplifying future trials of investigational new anti-tuberculosis [unreadable] [unreadable] [unreadable]..
  2. Clinical Outcomes Research in MDR-TB
    Carole Mitnick; Fiscal Year: 2008
    ..Mitnick's potential to pursue an independent research career as a chronic, infectious-disease epidemiologist. [unreadable] [unreadable] [unreadable] [unreadable]..